CRDF

Cardiff Oncology, Inc.

Tremor tracks 3 of its cancer trials.

Company-wide warning signs

These add points to every one of this company's trials.

None right now.

Trials

CRDFCardiff Oncology
10Calm
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation
FinishedPhase 223 patientsMain results: Dec 9, 2024
CRDFCardiff Oncology
0Calm
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
Running, no new patientsPhase 2110 patientsMain results: Nov 2026
CRDFCardiff Oncology
0Calm
Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation
FinishedPhase 1/268 patientsMain results: Jan 29, 2024

Key executives leaving

From the last 12 months of the company's SEC reports.

None found.

Insider trades (last 6 months)

“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.

0 sales (0 not pre-planned) · 4 purchases

PACE GARY WBoard member · Jul 14, 2026Bought 687,285 sharesabout $1000 thousand ·
Mohindru ManiChief Executive Officer · Jul 14, 2026Bought 34,364 sharesabout $50 thousand ·
Mohindru ManiChief Executive Officer · Jun 18, 2026Bought 24,703 sharesabout $30 thousand ·
PACE GARY WBoard member · Jun 18, 2026Bought 30,000 sharesabout $37 thousand ·

Recent SEC filings

Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.

Money left

Coming soon: how many months of cash the company has, from its quarterly reports.